Drug Profile
Human papillomavirus vaccine recombinant quadrivalent - Merck
Alternative Names: Gardasil; Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Merck; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Merck; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Merck; q HPV; Quadrivalent human papillomavirus vaccine - Merck; Silgard; V 501Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator CSL; The University of Queensland
- Developer Banyu; Chongqing Zhifei Biological Products; CSL; Merck & Co; Merck Sharp & Dohme; National Cancer Institute (USA); The EMMES Corporation; University of Arkansas System; University of California at San Francisco
- Class Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Condylomata acuminata; Gynaecological cancer; Human papillomavirus infections
- Phase III Penile cancer
Most Recent Events
- 30 Oct 2023 Merck completes a Phase-III clinical trial in Human papillomavirus infections (Prevention, In children, In adolescents, In adults) in China (IM)(NCT03493542)
- 27 Oct 2021 University of Alabama completes the phase II trial in Human-papillomavirus-infections (In children, In adolescent, In adults, Prevention) in USA (NCT01492582)
- 17 Feb 2021 No development reported - Phase-III for Human papillomavirus infections (Prevention) in Thailand (IM)